Efficacy subgroup analyses from the phase 3 CHAMPION-NMOSD trial in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (S5.003)
Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available
10.1212/wnl.0000000000203035